Page 10 of 49: studies 91 to 100 of 490, newest first. Back to the psilocybin for depression overview
Frontiers in Psychiatry 2026 Sofia Abramsky-Sze, Elliot Marseille, Richard Matzopoulos et al. correction
[This corrects the article DOI: 10.3389/fpsyt.2025.1508811.].
Medicinska istrazivanja 2026 Stefan Jerotić, Olga Čolović, Nađa Marić
Psychedelic-assisted psychotherapy (PAP) is emerging as a novel intervention for major psychiatric disorders, most notably major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). While psychotherapy is widely regarded as a core element of PAP its precise role remains poorly defined. This narrative review traces the development of PAP within contemporary Western psychiatry,...
Genetics and Molecular Research 2026 Mahvash Khan, Muhammad Omar Malik, Sara Sajjad et al.
Background: Major depressive disorder is a prevalent psychological condition that is characterized by sustained low mood, dysfunction and biological dysregulation. Depression can be treated with cognitive behavioral therapy, and newer studies indicate that psilocybin-based therapy may improve depressive symptoms when used under supervised psychological support. Oxytocin, a neuropeptide that...
Online Publication Service of Würzburg University (Würzburg University) 2026 Katja Ehrmann
Obsessive Compulsive Disorder (OCD) is a prevalent mental disorder, with a lifetime prevalence of 2-3%, characterized by intrusive thoughts (obsessions) and repetitive behaviors (compulsions). These thoughts and behaviors take up a significant amount of time, cause immense distress, and compromise the quality of life of those who suffer from OCD. In addition to psychological factors such as...
Annals of medicine and surgery (2012) 2026 Sana Rasheed, Rida Arif, Ahmed Asad Raza et al. 1 citation
Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), particularly in cases where traditional treatments prove ineffective. The study aims to evaluate psilocybin's therapeutic potential by examining its efficacy, safety, and mechanisms of action as well as addressing the societal and regulatory...
World journal of microbiology & biotechnology December 31, 2025 José Islas-Vargas, Silvia Armenta, Ángeles Alitzel Rivera-Román et al. 2 citations
Psilocybin, a tryptamine-derived alkaloid from Psilocybe mushrooms, has emerged as a high-value biopharmaceutical candidate due to its promising applications in mental health. While clinical studies highlight its rapid and sustained antidepressant effects, current challenges lie in achieving scalable, reproducible, and cost-effective production to meet growing research and therapeutic demand....
Journal of Clinical Medicine December 29, 2025 Monika Dominiak, Adam Gędek, Szymon Modrzejewski et al. 2 citations
Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing numbers of randomized controlled trials (RCTs) and meta-analyses, a comprehensive synthesis of the evidence across different substances and indications is lacking. This umbrella review aims to evaluate the effectiveness and safety of...
Psychedelic Medicine December 23, 2025 Anthony L. Back, Bonnie A. Mcgregor, Lindsay Billingsley et al. 1 citation
Background: Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to date have studied individual models of psilocybin therapy, but group models may offer increased access and benefits of community. Purpose: This technical report describes a group facilitation model developed for an food and drug administration...
Journal of the Pakistan Medical Association December 20, 2025 Maria Rasool, Taha Hannan, Muhammad Imam
Dear Editor, In view of ongoing global research on mental health, especially Major Depressive Disorder, we would like to draw attention to a psychedelic substance, Psilocybin, which has been emerging as a viable treatment option for MDD. Psilocybin is a psychedelic compound derived from certain mushrooms that acts on Serotonergic receptors (primarily 5HT-2A). Psychedelic substances have...
Irish Journal of Psychological Medicine December 18, 2025 Gurjot Brar, T. R. Jun. Burke, Andrew Gribben et al.
Abstract Objectives: Interest in psilocybin as a treatment for depression has risen over the past decade, fuelled by promising clinical trials and a rapidly evolving regulatory landscape. Media coverage plays a critical role in shaping public perceptions, yet little is known about how psilocybin is portrayed in global anglophone online news for the treatment of depression. Methods: This study...